Table 4.

Incidence of renal end points^a

End Point	Perindopril- Indapamide (No. of Events/Patient [%])	Placebo	HR (95% CI)	P	NNT
Progression of nephropathy
all renal events	1243/5569 (22.3)	1500/5571 (26.9)	0.79 (0.73 to 0.85)	<0.0001	20
progression of ≥1 albuminuria stage	1179/5436 (21.7)	1442/5412 (26.6)	0.78 (0.72 to 0.84)	<0.0001	18
new-onset microalbuminuria	1094/3995 (27.4)	1317/3991 (33.0)	0.79 (0.73 to 0.86)	<0.0001	16
new-onset macroalbuminuria	114/5436 (2.1)	163/5412 (3.0)	0.69 (0.54 to 0.88)	0.0027	97
patients with normoalbuminuria	25/3995 (0.6)	35/3991 (0.9)	0.71 (0.42 to 1.18)	0.1841	NA
patients with microalbuminuria	89/1441 (6.2)	128/1421 (9.0)	0.69 (0.52 to 0.91)	0.0074	32
doubling of serum creatinine >200 μmol/L	55/5569 (1.0)	45/5571 (0.8)	1.21 (0.81 to 1.79)	0.3483	NA
end-stage kidney diseaseb	25/5569 (0.4)	21/5571 (0.4)	1.18 (0.66 to 2.11)	0.5736	NA
Regression of nephropathy
regression of ≥1 albuminuria stage	908/1638 (55.4)	816/1625 (50.2)	1.16 (1.06 to 1.28)	0.0017	19
regression to normoalbuminuria	848/1638 (51.8)	745/1625 (45.8)	1.15 (1.04 to 1.27)	0.0059	16
patients with microalbuminuria	797/1441 (55.3)	698/1421 (49.1)	1.15 (1.04 to 1.27)	0.0067	16
patients with macroalbuminuria	51/197 (25.9)	47/204 (23.0)	1.08 (0.72 to 1.60)	0.7146	NA

^aNA, not applicable; NNT, number needed to treat to prevent one event of nephropathy progression or to promote one event of nephropathy regression over 5 yr.

^bDefined as requirement of renal replacement therapy or renal death.